Pharmaceutical Business review

Otsuka’s schizophrenia drug receives CHMP’s positive opinion

Abilify is intended for the treatment of schizophrenia. It is also indicated for the treatment of moderate to severe manic episodes in bipolar I Disorder and for the prevention of a new manic episode in patients who experienced predominantly manic episodes and whose manic episodes responded to aripiprazole treatment.